- Home
- VRNT vs ELVN Comparison
VRNT vs ELVN Comparison
Compare VRNT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNT
- ELVN
- Stock Information
- Founded
- VRNT 1994
- ELVN 2016
- Country
- VRNT United States
- ELVN United States
- Employees
- VRNT N/A
- ELVN N/A
- Industry
- VRNT EDP Services
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- VRNT Technology
- ELVN Health Care
- Exchange
- VRNT Nasdaq
- ELVN Nasdaq
- Market Cap
- VRNT 1.1B
- ELVN 1.2B
- IPO Year
- VRNT N/A
- ELVN 2020
- Fundamental
- Price
- VRNT $21.50
- ELVN $20.73
- Analyst Decision
- VRNT Buy
- ELVN Strong Buy
- Analyst Count
- VRNT 6
- ELVN 5
- Target Price
- VRNT $30.33
- ELVN $41.20
- AVG Volume (30 Days)
- VRNT 2.7M
- ELVN 747.2K
- Earning Date
- VRNT 09-03-2025
- ELVN 08-12-2025
- Dividend Yield
- VRNT N/A
- ELVN N/A
- EPS Growth
- VRNT 79.53
- ELVN N/A
- EPS
- VRNT 0.84
- ELVN N/A
- Revenue
- VRNT $896,006,000.00
- ELVN N/A
- Revenue This Year
- VRNT $7.65
- ELVN N/A
- Revenue Next Year
- VRNT $5.54
- ELVN N/A
- P/E Ratio
- VRNT $25.50
- ELVN N/A
- Revenue Growth
- VRNT N/A
- ELVN N/A
- 52 Week Low
- VRNT $14.15
- ELVN $13.30
- 52 Week High
- VRNT $37.31
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- VRNT 66.61
- ELVN 52.08
- Support Level
- VRNT $18.50
- ELVN $19.22
- Resistance Level
- VRNT $22.84
- ELVN $21.90
- Average True Range (ATR)
- VRNT 1.33
- ELVN 1.49
- MACD
- VRNT 0.40
- ELVN -0.19
- Stochastic Oscillator
- VRNT 79.88
- ELVN 39.43
About VRNT Verint Systems Inc.
Verint Systems Inc with its subsidiaries, helps brands provide Boundless customer experience (CX) automation. AI offers a solution, and that's where Verint comes in. It empowers brands with groundbreaking AI via a next-gen open platform. Its Verint Open Platform helps organizations increase CX automation to achieve their strategic objectives and realize ROI. Geographically, it derives a majority of its revenue from the United States.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.